Published: 28 October 2020
Author(s): Giulio Cavalli, Lorenzo Dagna
Issue: January 2021
Section: Commentary

In this issue of the Journal, Di Castelnuovo and colleagues report the findings of the observational multicentre Italian CORIST Study on the use of hydroxychloroquine (HCQ) in hospitalised COVID-19 patients [1]. In this large, retrospective cohort of 3,451 COVID-19 inpatients from 33 clinical centers, the use of HCQ was associated with a significant increase in survival. Specifically, the Authors reported an in-hospital death rate of 8.9 per 1,000 person-day for patients receiving HCQ, and of 15.7 for patients not receiving HCQ.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.